Table 4 Clinical characteristics, treatment and prognosis of 18 SPTCL cases
Age/sex | Extent of cutaneous lesions | B symptoms | HPS | Chemotherapy regimen | Relapse | Clinical stage | Prognosis |
|---|---|---|---|---|---|---|---|
12y/M(P1) | Multiple, extremities, face | No | No | NKT-like, IT | No | T1N1M0,IV | CR (76Â months) |
12y/F(P2) | Single, extremities | Yes | No | NKT-like, IT | No | T1N0M0 | CR (17Â months) |
10Â m/M(P3) | Single, extremities | No | No | NKT-like, IT | No | T1N0M0 | CR (17Â months) |
13y/F(P4) | Single, extremities | Yes | Yes | NKT-like | Yes | T1N1M0,IV | CR (26Â months), relapse |
11y/M(P5) | Single, trunk | Yes | No | ALL-like, IT | No | T3N0M0 | CR (58Â months) |
5Â m/M(P6) | Multiple, extremities, face | No | No | NKT-like, IT | No | T1N0M0 | CR (21Â months) |
2y/F(P7) | Multiple, extremities, trunk | Yes | No | NKT-like, IT | No | T1N1M0,IV | CR (34Â months) |
10y/F(P8) | Single, extremities | Yes | No | ALL-like, IT | No | T1N1M0,IV | CR (44Â months) |
11y/F(P9) | Multiple, extremities, trunk | No | Yes | HLA-04, Ruxo | No | T1N1MO,IV | CR (14Â months) |
12y/F(P10) | Single, trunk | Yes | Yes | HLA-04 | No | T1N0M0 | PR, Continue treatment |
10y/M(P11) | Single, perineum | Yes | Yes | Glucocorticoid, Ruxo, tacrolimus | No | T1N0M0 | CR (9Â months) |
12y/M(P12) | Single, face | Yes | No | ALL-like, IT | No | T1N1M0,IV | CR (74Â months) |
9y/F(P13) | Single, extremities | No | No | Prednisone, hydroxychloroquine | No | T3NxM1IVB | Disappeared spontaneously |
14y/M(P14) | Multiple, extremities, face | Yes | Yes | HLA-04 | No | T1N0M0 | CR (27Â months) |
12y/M(P15) | Multiple, extremities, face | Yes | Yes | Glucocorticoid, Ruxo | No | T1N0M0 | CR (10Â months) |
5y/M(P16) | Single, trunk | Yes | Yes | Glucocorticoid, Ruxo | Yes | T1N0M0 | ASCT, follow-up |
11Â m/M(P17) | Multiple, neck, face | No | No | Excision only | No | T1N0M0 | Follow-up (6Â months) |
11y/M(P18) | Multiple, extremities, trunk | No | No | ALL-like | No | T1N0M0 | Death |